Endomag, A Hologic Company

Endomag, a Hologic company based in Cambridge, UK, specializes in advanced surgical guidance technologies for breast cancer treatment. Founded in 2007 as a spin-out from University College London and the University of Houston, Endomag focuses on developing innovative, minimally invasive solutions to enhance treatment outcomes for patients globally. The company’s core products include Magseed®, a magnetic marker for tumor localization, Magtrace®, a magnetic injectable tracer for lymphatic mapping, and the Sentimag® platform, which supports both tumor localization and lymphatic tracing during surgery. These technologies enable more accurate and less invasive procedures, helping to improve patient outcomes and reduce unnecessary surgeries. Endomag's products are utilized in over 1,350 hospitals across more than 45 countries, benefiting over 500,000 women worldwide. The company’s mission emphasizes preventing unnecessary surgery, improving surgical outcomes, and enhancing the global standard of breast cancer care.

• Employees 150
• Founded 2007
• Annual Revenue $313900000
• Total Funding $42131160